Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

被引：13

作者：

Grana, G. ^{[1
]}

机构：

[1] Cooper Univ Hosp, Dept Hematol Oncol, Camden, NJ USA

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2006年 / 93卷 / 07期

关键词：

anastrozole; letrozole; exemestane; hormonal treatment; tamoxifen;

D O I：

10.1002/jso.20564

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive early breast cancer. However, the side-effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized trials of the third-generation aromatase inhibitors, anastrozole, letrozole and exemestane, demonstrating improved efficacy compared with tamoxifen and favorable tolerability profiles, are discussed in this review.

引用

页码：585 / 592

页数：8

共 28 条

[11] Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial [J].

Fisher, B ;

Dignam, J ;

Bryant, J ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :684-690

[12] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[13] Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17 [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, DS ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Cameron, DA ;

Palmer, MJ ;

Pater, JL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1262-1271

[14]

*GROUP EBCTC, 2005, COCHR LIB

[15]

Hendrix SL, 2001, ANN NY ACAD SCI, V949, P243

[16]

Howell A, 2004, BREAST CANCER RES TR, V88, pS7

[17] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[18]

Jakesz R, 2005, J CLIN ONCOL, V23, p10S

[19] Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial [J].

Jakesz, R ;

Jonat, W ;

Gnant, M ;

Mittlboeck, M ;

Greil, R ;

Tausch, C ;

Hilfrich, J ;

Kwasny, W ;

Menzel, C ;

Samonigg, H ;

Seifert, M ;

Gademann, G ;

Kaufmann, M .

LANCET, 2005, 366 (9484) :455-462

[20] Tamoxifen and risk of idiopathic venous thromboembolism [J].

Meier, CR ;

Jick, H .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) :608-612

← 1 2 3 →